SERB Pharmaceuticals Acquires Y-mAbs Therapeutics
September 16, 2025
SERB Pharmaceuticals completed its acquisition of Y-mAbs Therapeutics following a tender offer and statutory merger, making Y-mAbs a wholly owned subsidiary and delisting it from Nasdaq. The deal adds Y-mAbs' antibody-based oncology assets — including Danyelza (naxitamab-gqgk) — to SERB's rare disease and rare oncology portfolio to expand its commercial capabilities in pediatric and rare cancers.
- Buyers
- SERB Pharmaceuticals
- Targets
- Y-mAbs Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- New York, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.